Ragnhammar, P <br/><br/>
Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  Jun 1995 
 - 367-75 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0340-7004 
<br/><br/><label>Standard No.: </label>10.1007/BF01525387  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Anti-Idiotypic--biosynthesis<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Neoplasm--biosynthesis<br/>Colorectal Neoplasms--immunology<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Female<br/>Granulocyte-Macrophage Colony-Stimulating Factor--pharmacology<br/>Humans<br/>Immunoglobulin Isotypes--biosynthesis<br/>Immunotherapy<br/>Immunotoxins--adverse effects<br/>Male<br/>Middle Aged